Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

NCT01346787 is registered in ClinicalTrials.gov with European Myeloma Network B.V. as lead sponsor.

NCT NCT01346787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01346787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
Lead sponsor
European Myeloma Network B.V.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2011
Completion date
May 31, 2023
Enrollment
58 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma